Cart
sales@molnova.com
TH 257
CAS No. 2244678-29-1
TH 257( —— )
Catalog No. M20839 CAS No. 2244678-29-1
TH 257 is a Potent and selective allosteric LIMK 1/2 inhibitor(LIMK1 and LIMK2 IC50 of 84 nM and 39 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 53 | In Stock |
|
| 10MG | 84 | In Stock |
|
| 25MG | 168 | In Stock |
|
| 50MG | 292 | In Stock |
|
| 100MG | 472 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTH 257
-
NoteResearch use only, not for human use.
-
Brief DescriptionTH 257 is a Potent and selective allosteric LIMK 1/2 inhibitor(LIMK1 and LIMK2 IC50 of 84 nM and 39 nM).
-
DescriptionTH 257 is a Potent and selective allosteric LIMK 1/2 inhibitor(LIMK1 and LIMK2 IC50 of 84 nM and 39 nM).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetLIM Kinase (LIMK)
-
RecptorLIMK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2244678-29-1
-
Formula Weight422.5
-
Molecular FormulaC24H26N2O3S?
-
Purity>98% (HPLC)
-
SolubilityDMSO:250 mg/mL?(591.66 mM)
-
SMILESCCCCN(Cc1ccccc1)C(=O)c1ccc(S(=O)(=O)Nc2ccccc2)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Fabrizio M . Recent advances in the rational design and development of LIM kinase inhibitors are not enough to enter clinical trials[J]. European Journal of Medicinal Chemistry 2018:S0223523418305075-.
molnova catalog
related products
-
LX7101
LX7101 is a potent, dual LIMK and ROCK inhibitor with IC50 of 4.3/32//69/32/ nM for LIMK2/LIMK1/ROCK1/ROCK2, respectively.
-
TH 257
TH 257 is a Potent and selective allosteric LIMK 1/2 inhibitor(LIMK1 and LIMK2 IC50 of 84 nM and 39 nM).
-
R-10015
R-10015 is a potent and selective inhibitor of LIM domain kinase (LIMK) and binds to the ATP-binding pocket(IC50 of 38 nM for human LIMK1),and a broad-spectrum antiviral compound for HIV infection.R10015 as a lead compound that blocks LIMK activity by binding to the ATP-binding pocket.?
